BioPatent

Print Friendly

BioPatent

The aim of the project is to obtain international patent protection by preparing patent applications in the international procedure PCT (four patent applications).

There is a great need to provide intellectual property to companies involved in innovation activities in biotechnology, pharmaceuticals and diagnostics. In the current economic conditions and changes in the industry related to the reduction of expenditure on R&D activities and search for ready solutions, that is finished ones that are under limited risk. Implementation of the project increases the chances of industrial development within technological niches: pharmaceutical, biotechnological, diagnostic. These market areas are in Poland under development and this market, due to the technological progress is very absorbent and requires continuous creation and continuous supply of intellectual property generated outside the enterprise. There is a natural balance of supply and demand of intellectual property in the pharmaceutical, biotechnological and diagnostic areas.

In Poland there is a great need for providing modern formulations of drugs for the treatment of cancer. Among the representatives of the biotechnology and pharmaceutical industry the customers of solutions in the field of liposomal formulation of epirubicin but also techniques of nanoencapsulation of active substances can also be large companies and small and medium-sized enterprises.

Bovine serum albumin is produced by several companies, among others, EURx and POCH. However, the albumin being the product of the above companies does not have a degree of purification similar to that which is obtained as a result of the invention, therefore, there is a need to increase the purity and improve methods for preparation of this protein. The final recipient of the technology in this area can be a big business reagent such as Sigma-Aldrich, as well as tumour diagnostics market in Poland, which is under development. Also here small technology companies (eg. ReadGene) are of key importance in the transfer of technology indicating a high risk of investment for large companies such as Roche Diagnostics.

The above described inventions have a chance to enter the market only if they are covered by patent protection. In the era of globalization, Polish applications are not enough to what is needed for international protection, especially inventions in the pharmaceutical and biotechnology industry.

Applications planned in the project relate to inventions of:

Liposomes are microscopic spherical structures composed of the lipid bilayer. They take the form of single-layer or multilayer vesicles, in which various chemicals can be closed. Liposomes are used in cosmetics and medicine as carriers for active compounds, including anticancer drugs.

The use of this form of the drug has many benefits. It allows for the distribution of both hydrophilic and hydrophobic compounds, directs the delivery of pharmaceuticals to destinations, reduces their toxicity and protects against rapid biodegradation and through a long and gradual release of the drug prolongs its duration of action.

Despite the many known methods for preparing liposomes there is still a need to conduct intensive research to develop techniques to close the highest possible amount of drug in a minimum volume of the liposome, simultaneously obtaining non-toxic formulations with high durability.

The team of EIT+ Wrocław Research Centre has developed a liposomal formulation containing antitumour active substance and its manufacturing processes. The invented method allows a high entrapping of the drug and the preparation of stable liposome formulation which can be used in tumour therapy.

The invention is covered by the project: “International protection of inventions in the field of biotechnology, supporting the growth of competitiveness of Polish enterprises” implemented under the Operational Programme of Innovative Economy 2007-2013, Priority 1, Research and development of modern technologies Measure 1.3 Support for R&D projects for entrepreneurs carried out by scientific entities, Sub-measure 1.3.2 Support for the protection of industrial property generated in scientific entities as a result of R&D. Contract number: UDA-POIG.01.03.02-02-139/11-00.

Polymeric micelle – a carrier of active substances
Currently, one of the main goals of modern pharmaceutical technology is to improve the well-known therapy and development of new forms of drugs, so as to enhance their therapeutic effectiveness and minimize side effects by directly delivering them to a specific site of action.

Examples of structures that may act as carriers of active substances are polymeric micelles. These are spherical structures composed of a hydrophilic shell and a hydrophobic core, inside of which active substances are closed. The use of micelles allows for targeted drug transport to the affected tissue, controlling drug release, improving bioavailability and reduction of toxicity.

The team of EIT+ Wrocław Research Centre has developed a new carrier of polymeric micelles containing the active ingredients and the method for their preparation. The described method provides a highly stable nanocarriers possible to be used as modern systems of delivery of therapeutic substances, including as carriers for anticancer drugs.

The invention is covered by the project: “International protection of inventions in the field of biotechnology, supporting the growth of competitiveness of Polish enterprises” implemented under the Operational Programme of Innovative Economy 2007-2013, Priority 1, Research and development of modern technologies Measure 1.3 Support for R&D projects for entrepreneurs carried out by scientific entities, Sub-measure 1.3.2 Support for the protection of industrial property generated in scientific entities as a result of R&D. Contract number: UDA-POIG.01.03.02-02-139/11-00.

Ultra – pure albumin
Bovine serum albumin (BSA) is a protein commonly used in biochemistry and molecular biology. It is also commercially available. Its price is relatively low, but its purity is not satisfactory for many applications. In the case of basic research, where albumin is mainly used as a model protein, the purity of commercially available albumin is sufficient. The higher purity is, however, required for other applications. Albumin free of impurities (including sugar impurities) is required, inter alia, in clinical detection of proteins, metal ions, to construct vaccines, for producing selective antibodies or as a carrier of therapeutic agents in the treatment of inflammatory diseases or cancer.

So far, despite the high demand for high-quality albumin, there is a lack of fast and efficient methods of its purification.

The team of EIT+ Wrocław Research Centre has developed a simple method of obtaining, purifying and identifying ultra-pure bovine serum albumin form preparations commercially available. The use of this method will allow the introduction of higher quality albumin and verification of purity of the commercially available product.

The invention is covered by the project: “International protection of inventions in the field of biotechnology, supporting the growth of competitiveness of Polish enterprises” implemented under the Operational Programme of Innovative Economy 2007-2013, Priority 1, Research and development of modern technologies Measure 1.3 Support for R&D projects for entrepreneurs carried out by scientific entities, Sub-measure 1.3.2 Support for the protection of industrial property generated in scientific entities as a result of R&D. Contract number: UDA-POIG.01.03.02-02-139/11-00.

The method of diagnosis of thyroid cancer
Thyroid cancer is one of the most common cancers of the endocrine system. There are several types of cancer of the thyroid gland. Most commonly they are benign lesions called adenomas, less frequently malignant forms – adenocarcinomas.

Despite the significant development of diagnostic methods and prevalence of thyroid cancer, there are still great difficulties in differentiating the form of benign and malignant tumours. Currently, differentiation of thyroid cancer in malignant and benign from is performed mainly on the postoperative preparation, and the determination of their nature by aspiration fine needle biopsy is in most cases impossible. Therefore, there is an ongoing intensive search for new diagnostic techniques that will allow for accurate preoperative diagnosis of neoplastic changes and thereby reduce the number of unnecessary surgeries of removing the thyroid gland.

The team of EIT+ Wrocław Research Centre has developed a method and kit for the differentiation of neoplastic changes of the thyroid that allows to distinguish malignant changes from benign. Developed method is based on immunohistochemical measuring of the amount of protein as a diagnostic marker.

The use of the described method will complement previously used thyroid diagnostic techniques and will allow for differentiation of malignant neoplastic lesions from benign.

The invention is covered by the project: “International protection of inventions in the field of biotechnology, supporting the growth of competitiveness of Polish enterprises” implemented under the Operational Programme of Innovative Economy 2007-2013, Priority 1, Research and development of modern technologies Measure 1.3 Support for R&D projects for entrepreneurs carried out by scientific entities, Sub-measure 1.3.2 Support for the protection of industrial property generated in scientific entities as a result of R&D. Contract number: UDA-POIG.01.03.02-02-139/11-00.

Posted by , Posted on 28.08.2015
plusfontminusfontreloadfont